Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | USP36 | Q9P275 | 5/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5146356 | 0.81 | ILK (0.63) | ILKMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5147839 | 0.78 | ILK (0.59) | ILKMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5147785 | 0.77 | ILK (0.55) | ILKMEN1KMT2AALDH1A1HTT | |
| SCHEMBL5149415 | 0.76 | ILK (0.73) | ILKMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5146289 | 0.76 | ILK (0.73) | ILKMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5146331 | 0.74 | ILK (0.69) | ILKMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5147730 | 0.71 | ILK (0.64) | ILKMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5146290 | 0.71 | ILK (0.66) | ILKMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5147927 | 0.71 | ILK (0.77) | ILKMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5147923 | 0.71 | ILK (0.77) | ILKMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288556-B2 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7022702-B2 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2006-04-04 | — | — | US | disclosed |
| US-20060009500-A1 | Antiproliferative 1,2,3-thiadiazole compounds | QLT INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| US-20030096848-A1 | Antiproliferative 1,2,3-thiadiazole compounds | DERMIRA (CANADA), INC. | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096848-A1 | Antiproliferative 1,2,3-thiadiazole compounds | CCNA1, CCND1, CCND3 | ILK 1286/4885MEN1 2585/4885KMT2A 3558/4885 |
| US-20060009500-A1 | Antiproliferative 1,2,3-thiadiazole compounds | CCNA1, CCND3, ACIN1 | ILK 2862/4885MEN1 1548/4885KMT2A 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.